ICO
Closed:

Seeking Drug Candidates to Improve the Symptoms of NASH and Inhibit the Progression of Liver Fibrosis

Seeking Drug Candidates to Improve the Symptoms of NASH and Inhibit the Progression of Liver Fibrosis

EA Pharma Co. Ltd. wish to engage research that fulfils at least one of four requirements:

1. The discovery of drug candidates that improve the symptoms of NASH

Our client seeks to identify drug candidates that can improve Non-alcoholic fatty liver disease Activity Score (NAS) (i.e., hepatocellular fatty change, infiltration of inflammatory cells, and hepatocellular ballooning) and inhibit the progression of liver fibrosis. Priorities will be given to drug candidates fulfilling one or more of the criteria below:

  • Those involved in bile acid sensing or ...

To see the full details and submit your response please register now

Benefits of registration:

  • Receive updates on the latest industry calls
  • Quickly and easily respond to calls via your dashboard
  • Build your academic profile

Opportunity types being sought:

  • Technologies
  • Academics and expertise
  • Centres of excellence
  • Research projects
  • Spin-out companies

Essential Information

Submission Form

Share this call with professional partners.